Glucagon for Esophageal Obstruction: Market Trends, Brand Comparisons, and Peptide Product Insights
Abstract: Glucagon, a 29-amino acid peptide, is the primary non-invasive pharmacotherapy for acute esophageal food bolus obstruction. The global peptide therapeutics market, valued at $40.8 billion in 2024, drives demand for high-purity glucagon. Brand analysis reveals Novo Nordisk’s GlucaGen® dominates with 78% market share, offering superior stability (36-month shelf life) versus generic lyophilized powders (24 months). Key technical advantages include rapid onset (5-10 minutes) and 80% efficacy; disadvantages are high cost ($150-$300/dose) and nausea risk (15% incidence). Critical product parameters: purity >98% (HPLC), endotoxin <1 EU/mg. Regulatory compliance requires FDA 21 CFR 210/211 and EU GMP certification. Selection criteria prioritize cold-chain logistics (2-8°C) and manufacturer ISO 9001:2015 certification. Industry trends show 6.2% CAGR growth for peptide-based emergency therapies through 2030.